Blood taken for culture in adult with signs of infection

*S. aureus* grown

Physician decides and initiates standard antibiotic therapy empirically

<96hrs antibiotics received; if results available, sensitivity testing shows susceptibility to rifampicin; no contraindications to rifampicin; and rifampicin not mandated in judgement of the treating physician

RANDOMISE
940 CONSENTING PATIENTS* 1:1 TO

14 days blinded rifampicin added to standard antibiotic

14 days matched placebo added to standard antibiotic

**Follow-up:** day 3, 7, 14 then weekly whilst in hospital, and at discharge. Final follow-up at 12 weeks.

**Primary endpoints**: Death by 14 days or death or microbiologically confirmed treatment failure or disease recurrence by 12 weeks from enrolment

**Secondary endpoints**: Toxicity, drug interactions, new rifampicin resistance, clinically defined treatment failure or disease recurrence by 12 weeks from enrolment